| Literature DB >> 35011473 |
Melissa M Cadelis1,2, Natasha S L Nipper1, Alex Grey2, Soeren Geese2, Shara J van de Pas2, Bevan S Weir3, Brent R Copp1, Siouxsie Wiles2.
Abstract
Screening of several fungi from the New Zealand International Collection of Microorganisms from Plants identified two strains of Penicillium, P. bissettii and P. glabrum, which exhibited antimicrobial activity against Escherichia coli,Klebsiella pneumoniae, and Staphylococcus aureus. Further investigation into the natural products of the fungi, through extraction and fractionation, led to the isolation of five known polyketide metabolites, penicillic acid (1), citromycetin (2), penialdin A (3), penialdin F (4), and myxotrichin B (5). Semi-synthetic derivatization of 1 led to the discovery of a novel dihydro (1a) derivative that provided evidence for the existence of the much-speculated open-chained form of 1. Upon investigation of the antimicrobial activities of the natural products and derivatives, both penicillic acid (1) and penialdin F (4) were found to inhibit the growth of Methicillin-resistant S. aureus. Penialdin F (4) was also found to have some inhibitory activity against Mycobacterium abscessus and M. marinum along with citromycetin (2).Entities:
Keywords: antimicrobial; fungi; metabolite; natural products; penicillium
Mesh:
Substances:
Year: 2021 PMID: 35011473 PMCID: PMC8746583 DOI: 10.3390/molecules27010240
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of polyketide metabolites isolated from Penicillium.
Figure 2Antibacterial activity of Penicillium bissettii ICMP 21333 against Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus. The antibacterial activity of P. bissettii ICMP 21333 was measured by the production of zones of inhibition (mm) when fungal plugs were incubated on lawns of E. coli ATCC 25922, K. pneumoniae ATCC 700603, S. aureus ATCC 29213 (antibiotic-sensitive), and S. aureus ATCC 33593 (antibiotic-resistant). Boxes are upper and lower quartiles with median shown. The whiskers extend up to 1.5× the inter-quartile range, and any dots beyond those bounds are outliers. The dotted line represents the diameter of the fungal plugs. Experiments were performed on three separate occasions with three technical replicates per experiment.
Figure 3Tautomerization of penicillic acid (1).
Figure 4Structures of penicillic acid (1) and its derivatives (1a–1c).
1H and 13C NMR (CD3OD) signals observed for crude (1a) and purified (1b) products.
| Position | 1a | 1b | ||
|---|---|---|---|---|
| δH | δC | δH | δC | |
| 1 | 174.6 | 173.5 | ||
| 2 | 5.19 | 97.2 | 5.20 | 89.2 |
| 3 | 171.2 | 182.1 | ||
| 4 | 217.1 | 107.2 | ||
| 5 | Not observed | 39.3 | 2.12 | 34.6 |
| 6 | 1.07 | 17.5 | 1.04 | 16.1 |
| 6′ | 1.07 | 17.5 | 0.88 | 16.4 |
| 7 | 3.72 | 57.8 | 3.93 | 59.9 |
Relative Integral Values for 13C NMR Peaks Observed for 13C-labelled Penicillic Acid (1).
| Position | Δc | Relative Integral (Labelled/Unlabelled) |
|---|---|---|
| C-1 | 181.2 | 12.3 |
| C-2 | 90.1 | 1.0 |
| C-3 | 173.2 | 10.1 |
| C-4 | Not observed | |
| C-5 | 141.7 | 8.5 |
| C-6 | 116.7 | 1.1 |
| C-7 | 17.5 | 1.0 |
| C-8 | 60.4 | 0.9 |
Figure 5Labelling pattern observed in 13C NMR spectrum of penicillic acid (1) produced by cultures supplemented with 1-13C sodium acetate.
Antimicrobial and antifungal activities of natural products 1–4 and derivatives 1b and 1c.
| Compound | Percentage Inhibition at 32 µg/mL | ||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
|
| 53.07 **** | 26.11 *** | 18.06 * | −1.15 | 6.12 | 6.50 | 2.15 |
|
| −1.05 | 0.34 | 4.32 | 2.75 | −26.55 | 2.49 | 18.33 ** |
|
| 17.41 * | 5.15 | 9.34 | −10.06 | −11.88 | 2.56 | −7.04 |
|
| 14.22 | 11.16 | 13.49 | 4.70 | −4.31 | −1.86 | 1.11 |
|
| −7.23 | 13.60 | −7.65 | −4.08 | −24.24 | −2.20 | 20.72 ** |
|
| 71.52 **** | 9.29 | 15.62 * | 0.52 | 12.55 | 8.84 | 6.73 |
All values are presented as the mean (n = 2). Negative values represent increases in growth compared to the no-compound controls. Data were analysed using a two-way ANOVA with Dunn’s multiple comparison test. The adjusted p values of those compounds that were significantly different to the relevant no inhibition control are given by * (* p < 0.05; ** p < 0.005; *** p < 0.0005; **** p < 0.0001). a Staphylococcus aureus ATCC 43300 (MRSA) with vancomycin (MIC 1 μg/mL) used as a positive control; b Escherichia coli ATCC 25922 with colistin (MIC 0.125 μg/mL) used as a positive control; c Klebsiella pneumoniae ATCC 700603 with colistin (MIC 0.25 μg/mL) as a positive control; d Pseudomonas aeruginosa ATCC 27853 with colistin (MIC 0.25 μg/mL); e Acinetobacter baumanii ATCC 19606 with colistin (MIC 0.25 μg/mL) as a positive control; f Candida albicans ATCC 90028 with fluconazole (MIC 0.125 μg/mL) as a positive control; g Cryptococcus neoformans ATCC 208821 with fluconazole (MIC 8 μg/mL) as a positive control.
Figure 6Effect of citromycetin (2) and penialdin F (4) on the luminescence of Mycobacterium abscessus BSG301 and M. marinum BSG101. The antibacterial activity of citromycetin (2) and penialdin F (4) were measured by changes in bacterial luminescence. Data are presented as box and whisker plots of the area under the curve values calculated from luminescence readings taken over 72 h. Boxes are upper and lower quartiles with median shown. The whiskers extend up to 1.5 × the inter-quartile range. The dotted line represents the no-compound control.